What is the appropriate low‑dose doxepin regimen for insomnia, including recommended dosing, contraindications, and common side effects?

Low-Dose Doxepin for Insomnia: Dosing, Contraindications, and Side Effects

For patients with chronic insomnia who are unable or unwilling to receive cognitive behavioral therapy, low-dose doxepin at 3 mg or 6 mg taken once daily at bedtime is the recommended dose, with both doses showing equivalent efficacy for sleep maintenance. 1

Recommended Dosing

Start with 3 mg or 6 mg taken once nightly at bedtime. The evidence shows no significant difference in efficacy between these two doses for improving sleep maintenance and total sleep time 1, 2. Both doses:

• Significantly reduce wake time after sleep onset
• Increase total sleep time into the last third of the night
• Improve sleep efficiency
• Do NOT significantly improve sleep onset latency 3, 2

Key dosing considerations:

• The 3 mg dose may be preferable initially in elderly patients to minimize any potential adverse effects 4
• Effects are evident after a single dose and maintain efficacy for up to 12 weeks 5
• Maximum recommended dose for once-daily bedtime dosing is 150 mg, though this applies to depression treatment, not insomnia 4
• For insomnia specifically, do not exceed 6 mg - higher doses are not FDA-approved for this indication and carry different risk profiles 1

Contraindications and Precautions

Absolute contraindications (based on FDA labeling and tricyclic class effects):

• Glaucoma (particularly angle-closure glaucoma) 4
• Urinary retention 4
• Concurrent use with MAO inhibitors

Use with extreme caution or avoid in:

• Elderly patients with cognitive impairment - sedating drugs cause confusion and oversedation; start at the lowest dose and observe closely 4
• Patients with cardiac conduction abnormalities - tricyclics can cause QRS widening and dysrhythmias 4
• Severe hepatic or renal impairment - dose adjustment may be necessary 4
• Patients with depression or suicidal ideation - while low-dose doxepin has no black box warning for suicide risk, this risk cannot be excluded 1
• Respiratory conditions (sleep apnea, COPD) - though less concerning at low doses than with benzodiazepines

Side Effects

Most common side effects (though notably, adverse event rates did not differ significantly from placebo in clinical trials):

Central Nervous System:

• Somnolence - most frequent, tends to be dose-related 3, 2
• Headache - second most common 3, 2
• Drowsiness (most commonly noticed, tends to disappear with continued therapy) 4
• Confusion, disorientation, hallucinations (rare, more common in elderly) 4

Anticholinergic Effects:

• Dry mouth 4
• Blurred vision 4
• Constipation 4
• Urinary retention 4

Cardiovascular:

• Hypotension, hypertension, tachycardia (reported occasionally) 4
• Cardiac dysrhythmias in overdose - QRS widening is a significant toxicity indicator 4

Other:

• Dizziness, tinnitus 4
• Weight gain 4
• Allergic reactions (rash, edema, photosensitization) 4

Critical Safety Points

No evidence of physical dependence or withdrawal: Unlike benzodiazepines and Z-drugs, low-dose doxepin shows no rebound insomnia or withdrawal effects upon discontinuation 2, 5. No tapering is required when stopping low-dose doxepin 6.

Next-day residual effects: Studies found no significant next-day residual sedation with low-dose doxepin (3-6 mg), distinguishing it from many other hypnotics 3, 2.

Overdose risk: While low-dose doxepin appears safe at therapeutic doses, overdose with tricyclic antidepressants can be fatal, causing cardiac dysrhythmias, severe hypotension, convulsions, and CNS depression 4. This is primarily a concern with higher doses used for depression.

Duration of therapy: The evidence supports short-term use (up to 12 weeks documented), though the VA/DoD guidelines emphasize offering "a short course" when CBT-I is unavailable 1, 5.

Clinical Algorithm

1. Confirm insomnia phenotype: Low-dose doxepin is specifically effective for sleep maintenance insomnia (frequent awakenings, early morning awakening), NOT sleep onset insomnia 7, 2

2. Screen for contraindications: Check for glaucoma, urinary retention, cardiac conduction disease, severe cognitive impairment

3. Start with 3 mg at bedtime (especially in elderly or those with multiple comorbidities)

4. If inadequate response after 1-2 weeks, increase to 6 mg - no additional benefit expected beyond 6 mg for insomnia 1

5. Reassess efficacy at 4 weeks - if no improvement, consider alternative therapy rather than dose escalation

6. Monitor for anticholinergic effects particularly in elderly patients (confusion, urinary retention, constipation)